177 related articles for article (PubMed ID: 12014864)
1. Irinotecan/thalidomide in metastatic colorectal cancer.
Govindarajan R
Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):23-6. PubMed ID: 12014864
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan and thalidomide in metastatic colorectal cancer.
Govindarajan R
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):29-32. PubMed ID: 11204671
[TBL] [Abstract][Full Text] [Related]
3. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
[TBL] [Abstract][Full Text] [Related]
4. Effect of thalidomide on gastrointestinal toxic effects of irinotecan.
Govindarajan R; Heaton KM; Broadwater R; Zeitlin A; Lang NP; Hauer-Jensen M
Lancet; 2000 Aug; 356(9229):566-7. PubMed ID: 10950238
[TBL] [Abstract][Full Text] [Related]
5. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
Price T; Hill M
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
[TBL] [Abstract][Full Text] [Related]
6. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
Allegrini G; Di Paolo A; Cerri E; Cupini S; Amatori F; Masi G; Danesi R; Marcucci L; Bocci G; Del Tacca M; Falcone A
Cancer Chemother Pharmacol; 2006 Nov; 58(5):585-93. PubMed ID: 16680463
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan in the treatment of colorectal cancer.
Fuchs C; Mitchell EP; Hoff PM
Cancer Treat Rev; 2006 Nov; 32(7):491-503. PubMed ID: 16959432
[TBL] [Abstract][Full Text] [Related]
9. UFT plus calcium folinate/irinotecan in colorectal cancer.
Twelves C
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):51-4. PubMed ID: 10442362
[TBL] [Abstract][Full Text] [Related]
10. Update on European adjuvant trials with irinotecan for colorectal cancer.
Douillard JY; Barbarot V; Bennouna J
Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):13-5. PubMed ID: 12014862
[TBL] [Abstract][Full Text] [Related]
11. Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
Duffour J; Gourgou S; Desseigne F; Debrigode C; Mineur L; Pinguet F; Poujol S; Chalbos P; Bressole F; Ychou M
Cancer Chemother Pharmacol; 2007 Aug; 60(3):383-9. PubMed ID: 17124595
[TBL] [Abstract][Full Text] [Related]
12. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
Mitry E; Ducreux M; Rougier P
Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer.
Shimada Y; Rougier P; Pitot H
Eur J Cancer; 1996; 32A Suppl 3():S13-7. PubMed ID: 8943660
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan in the first-line treatment of colorectal cancer.
Saltz LB
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):54-8. PubMed ID: 9726092
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
Rothenberg ML
Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
[TBL] [Abstract][Full Text] [Related]
16. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.
Hecht JR; Blanke CD; Benson AB; Lenz HJ
Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):13-5. PubMed ID: 14569841
[TBL] [Abstract][Full Text] [Related]
18. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
Cunningham D; Glimelius B
Semin Oncol; 1999 Feb; 26(1 Suppl 5):6-12. PubMed ID: 10213009
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Venook AP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]